华东医药股份有限公司2024年度环境、社会及治理（ESG）报告

Huadong Medicine Co., Ltd.Environmental, Social and Governance (ESG) Report Contents About This ReportMessage from the Chairman0406 EnvironmentalGreen Development andEcological Harmony02 GovernanceForging Ahead with OurOriginal Aspiration ProductExcellence inInnovation, Quality as03 EmployeesGathering Talent andWisdom to Build aBrighter Future Together04 106108108Looking AheadAnnexesPerformance Data R&D and InnovationQuality and SafetyResponsible Services Employee RecruitmentTalent DevelopmentEmployee Care Environmental ManagementActions against Climate ChangeEmissions Management Corporate GovernanceRobust Operation Contributing to the Benefits ofHealthcarePromoting Public Health98100 About This Report Introduction This is the 2024 Environmental, Social and Governance (ESG) Report issued by Huadong Medicine Co., Ltd. This reportis prepared to elaborate the Company's practices and performance in sustainable development, social responsibilityfulfillment and other aspects, to respond to the expectations and demands of our stakeholders. This report intends to All information and data referenced in this report are sourced exclusively from official documents, statistical reports andfinancial statements of Huadong Medicine, as well as information related to sustainable development practices gathered,consolidated and audited across various functional departments and business units within the Company. The Board ofDirectors of the Company hereby undertakes that this report contains no false records or misleading statements, and takes Reporting Period This report covers the period from January 1, 2024 to December 31, 2024. To improve the comparability and completeness,some sections of this report may extend beyond the reporting period. Preparation BasisThis report is prepared in accordance with theShenzhen Stock Exchange Guidelines for Self-discipline Regulation of Listed Companies No. 17 – Sustainable Development Report (Trial) . Meanwhile, the report makes extensive reference to theSustainability Reporting Standards (GRI Standards), and also refers to and responds to the Sustainable Development Goals(SDGs) and theGuidelines on Corporate Social Responsibility Reporting for Chinese Enterprises (CASS-ESG 5.0) issued by the Reporting ScopeThe contents of this report relate to Huadong Medicine Co., Ltd. and its subsidiaries. Unless otherwise specified, the scope of this report is consistent with that of the Company's Annual Report. Appellation Description To enhance clarity of this report, the references "Huadong Medicine", "the Company", "We" or "the Joint-Stock Company" are Access This report includes both Chinese and English versions. It is available for download at the website of Shenzhen StockExchange (http:// www.szse.cn) or the Company's official website (https://www.eastchinapharm.com/), where you can find Feedback Email:ir@eastchinapharm.com hz000963@126.com Message from the Chairman Huadong Medicine maintained steady business growthand effectively enhanced its core competitiveness andindustry influence.We made solid progress in innovation andresearch and development (R&D), with a focus on key areassuch as endocrinology, oncology, and autoimmunity, andsuccessfully advanced the development and market launch ofmultiple innovative drugs. With the launch of products such as assessments throughout their lifecycle to strengthen oursupply chain's risk management and resilience, ensuring asecure and reliable medical product assurance system forpatients, and fostering the sustainable development of the With an inclusive and open mindset, we continuouslyoptimized our human resources management system andbuilt a diversified talent development platform, providingemployees with broad career development opportunities.Weremained committed to safeguarding employees' rights and Inspired by dedication and perseverance, we laid a solidfoundation for the high-quality development of the Company. With the pursuit of a benevolent heart and skillful hands,we upheld a patient-centered approach and continuouslyimproved the accessibility and affordability of medications.By accelerating the market launch of innovative drugs andsupporting patient assistance programs, we enabled more We integrated social responsibility and the concept ofsustainable development into the core of our strategy andcontinued to advance the construction of the ESG system, fulfillingour corporate social responsibility through concrete actions.We have established a three-tier ESG governance structure toensure the top-down implementation of sustainability initiatives Lv Liang Chairman of HuadongMedicine Co., Ltd. When the tide is calm and the wind is fair, it is the right time toset sail and forge ahead. Looking ahead, Huadong Medicinewill fully implement the concept of sustainable development,actively fulfill its social responsibilities, and promote theCompany's high-quality development. We will continue toincrease R&D investmen